More expansive diagnosis and treatment are urgently needed to eliminate the global burden of HBV.
作者信息
Liu Yi, Yuan Xiao, Ji Fanpu
机构信息
Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
出版信息
Lancet Reg Health Am. 2024 Jul 16;36:100843. doi: 10.1016/j.lana.2024.100843. eCollection 2024 Aug.
Abstract
摘要
相似文献
1
More expansive diagnosis and treatment are urgently needed to eliminate the global burden of HBV.迫切需要更广泛的诊断和治疗以消除全球乙肝负担。
Lancet Reg Health Am. 2024 Jul 16;36:100843. doi: 10.1016/j.lana.2024.100843. eCollection 2024 Aug.
2
Global strategies are required to cure and eliminate HBV infection.需要采取全球策略来治愈和消除乙肝病毒感染。
Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):239-48. doi: 10.1038/nrgastro.2016.7. Epub 2016 Feb 24.
3
What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats.消除乙型肝炎病毒和丙型肝炎病毒作为全球健康威胁需要什么。
Gastroenterology. 2019 Jan;156(2):297-310. doi: 10.1053/j.gastro.2018.10.048. Epub 2018 Nov 2.
4
Mother-to-child transmission of hepatitis B: What more needs to be done to eliminate it around the world?乙型肝炎母婴传播：全球范围内还需要做哪些工作来消除它？
J Viral Hepat. 2020 Apr;27(4):342-349. doi: 10.1111/jvh.13231. Epub 2020 Jan 23.
5
Global elimination of HBV: Is it really achievable?全球消除乙肝病毒：真的可以实现吗？
J Viral Hepat. 2024 Dec;31 Suppl 2(Suppl 2):4-12. doi: 10.1111/jvh.13955. Epub 2024 May 26.
6
Awareness and treatment of chronic hepatitis B in Malaysia-findings from a community-based screening campaign.马来西亚慢性乙型肝炎的认知和治疗-基于社区筛查活动的研究结果。
BMC Gastroenterol. 2022 Aug 6;22(1):374. doi: 10.1186/s12876-022-02458-9.
7
Impact of the 2008 economic crisis on the burden of hepatitis B and C diseases in Southern European countries.2008 年经济危机对南欧国家乙型和丙型肝炎疾病负担的影响。
BMC Public Health. 2024 Jun 20;24(1):1642. doi: 10.1186/s12889-024-18912-0.
8
A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals.全球视角下的乙型肝炎病毒慢性感染：免疫功能正常个体的诊断、治疗和预防的新策略。
Int J Environ Res Public Health. 2019 Sep 9;16(18):3307. doi: 10.3390/ijerph16183307.
9
Hepatitis B and C in Europe: an update from the Global Burden of Disease Study 2019.欧洲的乙型肝炎和丙型肝炎：来自 2019 年全球疾病负担研究的最新更新。
Lancet Public Health. 2023 Sep;8(9):e701-e716. doi: 10.1016/S2468-2667(23)00149-4.
10
Development of DHQ-based chemical biology probe to profile cellular targets for HBV.基于 DHQ 的化学生物学探针用于鉴定 HBV 的细胞靶标。
Bioorg Med Chem Lett. 2020 Dec 1;30(23):127615. doi: 10.1016/j.bmcl.2020.127615. Epub 2020 Oct 17.
引用本文的文献
1
Global burden and trends of viral hepatitis among women of childbearing age from 1990 to 2021.1990年至2021年育龄妇女中病毒性肝炎的全球负担及趋势
Front Microbiol. 2025 Feb 21;16:1553129. doi: 10.3389/fmicb.2025.1553129. eCollection 2025.
本文引用的文献
1
Association of hepatitis B virus treatment with all-cause and liver-related mortality among individuals with HBV and cirrhosis: a population-based cohort study.乙肝病毒治疗与乙肝和肝硬化患者全因死亡率及肝脏相关死亡率的关联：一项基于人群的队列研究
Lancet Reg Health Am. 2024 Jun 28;36:100826. doi: 10.1016/j.lana.2024.100826. eCollection 2024 Aug.
2
Sex and ethnic disparities in hepatitis B evaluation and treatment across the world.全球乙型肝炎评估和治疗中的性别和种族差异。
J Hepatol. 2024 Jul;81(1):33-41. doi: 10.1016/j.jhep.2024.02.033. Epub 2024 May 1.
3
Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B.长期使用富马酸替诺福韦二吡呋酯会增加老年慢性乙型肝炎患者骨折风险。
J Hepatol. 2024 Apr;80(4):553-563. doi: 10.1016/j.jhep.2023.12.001. Epub 2023 Dec 14.
4
Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people.1973 年至 2021 年中国慢性乙型肝炎病毒感染流行率变化：3740 项研究和 2.31 亿人群的系统文献回顾和荟萃分析。
Gut. 2023 Nov 24;72(12):2354-2363. doi: 10.1136/gutjnl-2023-330691.
5
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.2022年全球乙型肝炎的流行率、照护流程及预防覆盖率：一项建模研究
Lancet Gastroenterol Hepatol. 2023 Oct;8(10):879-907. doi: 10.1016/S2468-1253(23)00197-8. Epub 2023 Jul 27.
6
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.抗病毒治疗可大幅降低处于不确定阶段的慢性乙型肝炎感染患者患肝癌的风险。
Hepatology. 2023 Nov 1;78(5):1558-1568. doi: 10.1097/HEP.0000000000000459. Epub 2023 May 16.
7
Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study).核苷（酸）类似物停药后肝失代偿的发生率：来自一项大型、国际性、多民族慢性乙型肝炎患者队列的研究结果（RETRACT-B 研究）。
Am J Gastroenterol. 2023 Sep 1;118(9):1601-1608. doi: 10.14309/ajg.0000000000002203. Epub 2023 Jan 30.
8
Stigma: a major barrier to hepatitis B elimination.耻辱感：消除乙型肝炎的主要障碍。
Nat Rev Gastroenterol Hepatol. 2022 Oct;19(10):622. doi: 10.1038/s41575-022-00670-2.
9
Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.中国慢性乙型肝炎病毒感染的普遍筛查的成本效益：经济评估。
Lancet Glob Health. 2022 Feb;10(2):e278-e287. doi: 10.1016/S2214-109X(21)00517-9.
10
Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States.美国私人保险患者慢性乙型肝炎的诊断率。
JAMA Netw Open. 2020 Apr 1;3(4):e201844. doi: 10.1001/jamanetworkopen.2020.1844.
Zotero 插件